Agriculture Secretary Tom Vilsack has testified on the pending legislation to reform and reauthorize USDA’s Child Nutrition Programs and Supplemental Nutrition Program for Women, Infants and Children (WIC) before the U.S. House of Representatives Committee on Education and Labor. Below are excerpts from Secretary Vilsack’s prepared testimony: “The Administration is strongly committed to passing legislation this year that reduces child hunger and improves the quality of school meals and the health of the school environment. “I thank Chairman Miller for his leadership on this issue…
Continue Read…
Cerapedics, Inc., a medical device company focused on developing and commercializing novel osteobiologic products, announced that it received the CE Mark for its i-FACTOR™ Flex bone graft product line. i-FACTOR Flex is the company’s second product in the i-FACTOR product platform based on its proprietary small peptide attachment factor technology. i-FACTOR bone graft is the only biologic bone graft that combines a unique anorganic bone mineral (ABM) and small peptide (P-15™) to act as an attachment factor for specific integrins on osteogenic cells…
Continue Read…
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) announced positive results in a Phase II study of the Pill-Plus “triple hormone” oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (pThe study was a Phase II double-blind randomized clinical trial in 82 women comprising a cross-over design of two treatment periods of five months each. The study compared use of an OC alone to the same OC with the addition of an oral androgen (DHEA). The study was performed by Dr. Rik van Lunsen and Dr…
Continue Read…
Eisai Inc. announced preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults. The primary endpoint of this study was overall survival. Although Dacogen did not reach statistically significant superiority over the control arm, a trend was evident…
Continue Read…
